Swiss deeptech startup Xsensio has closed an oversubscribed €6 million Series A financing round to advance its Lab-on-Skin wearable biosensing platform. The round was led by WI Harper Group, with participation from Privilège Ventures, the European Innovation Council (EIC), Propelx, and Swiss Health Angels.
Xsensio’s Lab-on-Skin platform integrates multiple biosensors onto an ultra-miniaturized chip capable of continuously monitoring biomarkers such as proteins, hormones, ions, and metabolites from interstitial fluid on the skin. Its modular design allows adaptation across clinical applications, giving healthcare professionals near real-time biochemical insights at the point of care.
“This Series A marks a pivotal step in translating continuous biochemical monitoring into real clinical environments. For the first time, clinicians can access key continuous biochemical data in real time, information that has historically been unavailable at the point of care,” says Esmeralda Megally, CEO of Xsensio.
The funding will accelerate clinical validation, support industrial-scale deployment, and expand partnerships, including a collaboration with Texas Instruments to advance miniaturization, CMOS integration, and large-scale manufacturability. Xsensio aims to transform patient monitoring and treatment by bringing continuous biochemical data directly to clinicians in hospitals and home care settings.
